RESEARCH TRIANGLE PARK, N.C., June 08, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 30, 2018 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 7, 2018. Detailed results of the vote for the election of directors are set out below:
| |
|
|
|
|
| Name of Nominee |
Votes For |
% Votes For |
Votes Withheld |
% Votes Withheld |
| Dr. Khalid Islam |
9,766,926 |
92.47% |
795,329 |
7.53% |
| Mr. Adrian Haigh |
9,767,181 |
92.47% |
795,074 |
7.53% |
| Mr. Chris A. Rallis |
9,765,833 |
92.46% |
796,422 |
7.54% |
| Mr. Marco Brughera |
10,558,689 |
99.97% |
3,566 |
0.03% |
| Mr. Rostislav Raykov |
10,559,584 |
99.97% |
2,671 |
0.03% |
| |
|
|
|
|
Shareholders voted 99.90% in favour of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 97.46% in favour of the compensation paid to the Company’s named executive officers, and 92.27% in favour of the extension of certain outstanding options held by certain of the Company’s officers.
For further information, please contact:
Rosty Raykov
Chief Executive Officer
Fennec Pharmaceuticals Inc.
T: (919) 636-5144
Source: Fennec Pharmaceuticals Inc.
